- Scancell, a developer of immunotherapies for the treatment of cancer, has partnered with the charity Cancer Research UK to develop Scancell's ImmunoBody vaccine, SCIB2, for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC).

Scancell's ImmunoBody immunotherapy platform activates the body's immune system by enhancing the uptake and presentation of cancer antigens to help target and eliminate cancer cells.

SCIB2, Scancell's second ImmunoBody therapy, targets an antigen called NY-ESO-1, which is expressed on a range of solid tumours, including NSCLC and oesophageal, ovarian, bladder and prostate cancers, as well as neuroblastoma, melanoma and sarcoma.

Cancer Research UK will fund and sponsor a UK-based Phase 1/2 clinical trial of SCIB2 in combination with a checkpoint inhibitor in patients with solid tumours, focusing on NSCLC in the first instance. The charity's Centre for Drug Development (CDD) will be responsible for manufacturing the clinical trial supplies of SCIB2, conducting pre-clinical testing, sponsoring and managing the clinical trial, including the clinical trial timelines.

Following completion of the Phase 1/2 clinical trial, Scancell will have the option to acquire the rights to the data to support further development of SCIB2 itself. If Scancell elects not to exercise the option, Cancer Research UK will retain the right to take the SCIB2 programme forward in all indications.

Professor Lindy Durrant, chief scientific officer of Scancell, said: "The charity's world-renowned expertise will no doubt be invaluable as we progress SCIB2 through the clinic. In pre-clinical studies, we have shown that a combination of SCIB2 and checkpoint inhibition produces enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. We believe SCIB2 has the potential to provide a much needed treatment option for patients suffering from a range of common solid tumours."

At 8:07am: [LON:SCLP] Scancell Holdings PLC share price was +1.5p at 14p

Story provided by